You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMefenamic acid
Accession NumberDB00784  (APRD00730)
TypeSmall Molecule
GroupsApproved
Description

A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase. [PubChem]

Structure
Thumb
Synonyms
Acide méfénamique
Acido mefenamico
Acidum mefenamicum
CI-473
CN 35355
CN-35355
INF 3355
INF-3355
Mefenaminsaeure
Mefenaminsäure
N-(2,3-Xylyl)-2-aminobenzoic acid
N-2,3-Xylylanthranilic acid
Ponstel
External Identifiers
  • CI 473
  • CN 35355
  • INF 3355
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-mefenamic Acidcapsule250 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Mefenamiccapsule250 mgoralAa Pharma Inc1996-11-06Not applicableCanada
Mefenamic Acidcapsule250 mg/1oralPrasco Laboratories2011-07-112016-04-05Us
Mefenamic-250capsule250 mgoralPro Doc Limitee1997-08-062009-07-23Canada
Novo-mefenamic Capsules 250mgcapsule250 mgoralNovopharm LimitedNot applicableNot applicableCanada
Nu-mefenamic 250 mgcapsule250 mgoralNu Pharm Inc1996-10-162012-09-04Canada
PMS-mefenamic Acidcapsule250 mgoralPharmascience Inc1998-04-16Not applicableCanada
Ponstancapsule250 mgoralErfa Canada 2012 Inc1966-12-31Not applicableCanada
Ponstelcapsule250 mg/1oralShionogi Inc.1967-03-282016-04-05Us
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mefenamic Acidcapsule250 mg/1oralPaddock Laboratories, LLC2010-11-192016-03-01Us
Mefenamic Acidcapsule250 mg/1oralSolubiomix2016-03-232016-04-01Us
Mefenamic Acidcapsule250 mg/1oralLUPIN PHARMACEUTICALS INC2011-07-222016-04-05Us
Mefenamic Acidcapsule250 mg/1oralBelcher Pharmaceuticals,LLC2015-06-252016-04-05Us
Mefenamic Acidcapsule250 mg/1oralBreckenridge Pharmaceutical, Inc.2014-10-132016-04-05Us
Mefenamic Acidcapsule250 mg/1oralQualitest Pharmaceuticals2014-06-022016-04-23Us
Over the Counter ProductsNot Available
International Brands
NameCompany
CoslanParke Davis
LysalgoSIT
MefacitSecFarm
ParkemedPfizer
PonalarCoronet Crown
Ponstan FortePfizer
PonstylPfizer
Ponstyl FortPfizer
PontalDaiichi Sankyo
TanstonPfizer
Brand mixturesNot Available
SaltsNot Available
Categories
UNII367589PJ2C
CAS number61-68-7
WeightAverage: 241.2851
Monoisotopic: 241.110278729
Chemical FormulaC15H15NO2
InChI KeyInChIKey=HYYBABOKPJLUIN-UHFFFAOYSA-N
InChI
InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)
IUPAC Name
2-[(2,3-dimethylphenyl)amino]benzoic acid
SMILES
CC1=C(C)C(NC2=CC=CC=C2C(O)=O)=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminobenzoic acids
Alternative Parents
Substituents
  • Aminobenzoic acid
  • Benzoic acid
  • Substituted aniline
  • Benzoyl
  • Aniline
  • Vinylogous amide
  • Secondary amine
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of rheumatoid arthritis, osteoarthritis, dysmenorrhea, and mild to moderate pain, inflammation, and fever.
PharmacodynamicsMefenamic acid, an anthranilic acid derivative, is a member of the fenamate group of nonsteroidal anti-inflammatory drugs (NSAIDs). It exhibits anti-inflammatory, analgesic, and antipyretic activities. Similar to other NSAIDs, mefenamic acid inhibits prostaglandin synthetase.
Mechanism of actionMefenamic acid binds the prostaglandin synthetase receptors COX-1 and COX-2, inhibiting the action of prostaglandin synthetase. As these receptors have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity, the symptoms of pain are temporarily reduced.
Related Articles
AbsorptionMefenamic acid is rapidly absorbed after oral administration.
Volume of distribution
  • 1.06 L/kg [Normal Healthy Adults (18-45 yr)]
Protein binding90%
Metabolism

Mefenamic acid undergoes metabolism by CYP2C9 to 3-hydroxymethyl mefenamic acid, and further oxidation to a 3-carboxymefenamic acid may occur. The activity of these metabolites has not been studied. Mefenamic acid is also glucuronidated directly.

Route of eliminationThe fecal route of elimination accounts for up to 20% of the dose, mainly in the form of unconjugated 3-carboxymefenamic acid.3 The elimination half-life of mefenamic acid is approximately two hours. Mefenamic acid, its metabolites and conjugates are primarily excreted by the kidneys. Both renal and hepatic excretion are significant pathways of elimination.
Half life2 hours
Clearance
  • Oral cl=21.23 L/hr [Healthy adults (18-45 yrs)]
ToxicityOral, rat LD50: 740 mg/kg. Symptoms of overdose may include severe stomach pain, coffee ground-like vomit, dark stool, ringing in the ears, change in amount of urine, unusually fast or slow heartbeat, muscle weakness, slow or shallow breathing, confusion, severe headache or loss of consciousness.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Mefenamic Acid Action PathwayDrug actionSMP00109
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.762
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.7948
P-glycoprotein inhibitor INon-inhibitor0.8632
P-glycoprotein inhibitor IINon-inhibitor0.9147
Renal organic cation transporterNon-inhibitor0.9191
CYP450 2C9 substrateNon-substrate0.6814
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7019
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9483
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9175
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6613
Ames testNon AMES toxic0.812
CarcinogenicityNon-carcinogens0.5833
BiodegradationNot ready biodegradable0.822
Rat acute toxicity2.5445 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9727
hERG inhibition (predictor II)Non-inhibitor0.8706
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shionogi pharma inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral250 mg/1
Capsuleoral250 mg
Prices
Unit descriptionCostUnit
Ponstel 250 mg capsule11.85USD capsule
Mefenamic acid powder2.85USD g
Ponstel 250 mg kapseals1.59USD each
Apo-Mefenamic 250 mg Capsule0.52USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point230-231 °CPhysProp
water solubility20 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP5.12HANSCH,C ET AL. (1995)
logS-3.78ADME Research, USCD
pKa4.2SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0137 mg/mLALOGPS
logP4.58ALOGPS
logP5.4ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)3.89ChemAxon
pKa (Strongest Basic)-1.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area49.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.88 m3·mol-1ChemAxon
Polarizability26.22 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesM01AG01
AHFS Codes
  • 28:08.04.92
PDB EntriesNot Available
FDA labelDownload (135 KB)
MSDSDownload (59.7 KB)
Interactions
Drug Interactions
Drug
AbciximabMefenamic acid may increase the anticoagulant activities of Abciximab.
AcenocoumarolMefenamic acid may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Acetylsalicylic acid.
AliskirenMefenamic acid may decrease the antihypertensive activities of Aliskiren.
AlteplaseMefenamic acid may increase the anticoagulant activities of Alteplase.
AmikacinMefenamic acid may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmitriptylineAmitriptyline may increase the antiplatelet activities of Mefenamic acid.
AnistreplaseMefenamic acid may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Apixaban.
ArbekacinMefenamic acid may decrease the excretion rate of Arbekacin which could result in a lower serum level and potentially a reduction in efficacy.
BalsalazideMefenamic acid may increase the nephrotoxic activities of Balsalazide.
Citric AcidMefenamic acid may increase the anticoagulant activities of Citric Acid.
ColesevelamColesevelam can cause a decrease in the absorption of Mefenamic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
CollagenaseThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Collagenase.
CyclosporineMefenamic acid may increase the nephrotoxic activities of Cyclosporine.
Dabigatran etexilateMefenamic acid may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinMefenamic acid may increase the anticoagulant activities of Dalteparin.
DasatinibDasatinib may increase the anticoagulant activities of Mefenamic acid.
DeferasiroxThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Deferasirox.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Deoxycholic Acid.
DesmopressinThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mefenamic acid.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mefenamic acid.
DicoumarolMefenamic acid may increase the anticoagulant activities of Dicoumarol.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mefenamic acid.
DrospirenoneMefenamic acid may increase the hyperkalemic activities of Drospirenone.
Edetic AcidMefenamic acid may increase the anticoagulant activities of Edetic Acid.
EnoxaparinMefenamic acid may increase the anticoagulant activities of Enoxaparin.
EplerenoneMefenamic acid may decrease the antihypertensive activities of Eplerenone.
Ethyl biscoumacetateMefenamic acid may increase the anticoagulant activities of Ethyl biscoumacetate.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mefenamic acid.
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mefenamic acid.
Fondaparinux sodiumMefenamic acid may increase the anticoagulant activities of Fondaparinux sodium.
FramycetinMefenamic acid may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
GentamicinMefenamic acid may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GlucosamineGlucosamine may increase the antiplatelet activities of Mefenamic acid.
HaloperidolThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Haloperidol.
HeparinMefenamic acid may increase the anticoagulant activities of Heparin.
HomoharringtonineThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Homoharringtonine.
HydralazineMefenamic acid may decrease the antihypertensive activities of Hydralazine.
IbritumomabThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Mefenamic acid.
IcosapentThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Icosapent.
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Mefenamic acid.
KanamycinMefenamic acid may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mefenamic acid.
LimaprostLimaprost may increase the antiplatelet activities of Mefenamic acid.
LithiumThe serum concentration of Lithium can be increased when it is combined with Mefenamic acid.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mefenamic acid.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mefenamic acid.
NadololMefenamic acid may decrease the antihypertensive activities of Nadolol.
NeomycinMefenamic acid may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NetilmicinMefenamic acid may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
ObinutuzumabThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Obinutuzumab.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Mefenamic acid.
PamidronateThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pamidronate.
ParoxetineParoxetine may increase the antiplatelet activities of Mefenamic acid.
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Mefenamic acid.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Mefenamic acid.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Mefenamic acid.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Mefenamic acid.
PhenindioneMefenamic acid may increase the anticoagulant activities of Phenindione.
PhenprocoumonMefenamic acid may increase the anticoagulant activities of Phenprocoumon.
PorfimerMefenamic acid may increase the photosensitizing activities of Porfimer.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mefenamic acid.
ProbenecidThe serum concentration of Mefenamic acid can be increased when it is combined with Probenecid.
ReteplaseMefenamic acid may increase the anticoagulant activities of Reteplase.
RibostamycinMefenamic acid may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RidogrelMefenamic acid may increase the anticoagulant activities of Ridogrel.
RivaroxabanMefenamic acid may increase the anticoagulant activities of Rivaroxaban.
SparfloxacinMefenamic acid may increase the neuroexcitatory activities of Sparfloxacin.
SpectinomycinMefenamic acid may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptokinaseMefenamic acid may increase the anticoagulant activities of Streptokinase.
StreptomycinMefenamic acid may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
SulodexideMefenamic acid may increase the anticoagulant activities of Sulodexide.
TacrolimusMefenamic acid may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mefenamic acid.
TenecteplaseMefenamic acid may increase the anticoagulant activities of Tenecteplase.
TenofovirThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tenofovir.
TipranavirTipranavir may increase the antiplatelet activities of Mefenamic acid.
TobramycinMefenamic acid may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TorasemideMefenamic acid may decrease the diuretic activities of Torasemide.
TositumomabThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Tositumomab.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mefenamic acid.
TriamtereneMefenamic acid may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mefenamic acid.
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mefenamic acid.
UrokinaseMefenamic acid may increase the anticoagulant activities of Urokinase.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mefenamic acid.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mefenamic acid.
VenlafaxineVenlafaxine may increase the antiplatelet activities of Mefenamic acid.
VerteporfinMefenamic acid may increase the photosensitizing activities of Verteporfin.
Vitamin EVitamin E may increase the antiplatelet activities of Mefenamic acid.
WarfarinMefenamic acid may increase the anticoagulant activities of Warfarin.
Food Interactions
  • Avoid alcohol.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305 ( Pt 2):479-84. [PubMed:7832763 ]
  2. Bhat AS, Tandan SK, Kumar D, Krishna V, Prakash VR: Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in adjuvant-induced arthritis in female albino rats: an isobolographic study. Eur J Pharmacol. 2007 Feb 5;556(1-3):190-9. Epub 2006 Oct 27. [PubMed:17150210 ]
  3. Bhat AS, Tandan SK, Kumar D, Krishna V, Prakash VR: Interaction between inhibitors of inducible nitric oxide synthase and cyclooxygenase in Brewer's yeast induced pyrexia in mice: an isobolographic study. Eur J Pharmacol. 2005 Mar 28;511(2-3):137-42. [PubMed:15792781 ]
  4. Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998 May;104(5):413-21. [PubMed:9626023 ]
  5. Walton LJ, Franklin IJ, Bayston T, Brown LC, Greenhalgh RM, Taylor GW, Powell JT: Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation. 1999 Jul 6;100(1):48-54. [PubMed:10393680 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Sinniah R, Lye WC: Acute renal failure from hemoglobinuric and interstitial nephritis secondary to iodine and mefenamic acid. Clin Nephrol. 2001 Mar;55(3):254-8. [PubMed:11316248 ]
  2. Joo Y, Kim HS, Woo RS, Park CH, Shin KY, Lee JP, Chang KA, Kim S, Suh YH: Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models. Mol Pharmacol. 2006 Jan;69(1):76-84. Epub 2005 Oct 13. [PubMed:16223958 ]
  3. Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998 May;104(5):413-21. [PubMed:9626023 ]
  4. Gierse JK, Hauser SD, Creely DP, Koboldt C, Rangwala SH, Isakson PC, Seibert K: Expression and selective inhibition of the constitutive and inducible forms of human cyclo-oxygenase. Biochem J. 1995 Jan 15;305 ( Pt 2):479-84. [PubMed:7832763 ]
  5. Laudanno OM, Cesolari JA, Esnarriaga J, Flaherty P, Vada J, Guastalli G, San Miguel P, Bedini OA: [In vivo selectivity of nonsteroidal anti-inflammatory drugs on COX-1-COX-2 and gastrointestinal ulcers, in rats]. Acta Gastroenterol Latinoam. 1998;28(3):249-55. [PubMed:9773153 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on November 24, 2013 14:27